Publications by authors named "N Mezzina"
We report the case of a 75-year-old man who developed acute myocardial infarction 12 hours after the first dose of ChAdOx1 nCov-19 vaccine. The event was associated with a transient decrease of platelet count and the detection of anti-PF4 antibodies approximately 45 days after the event. Vaccine-induced thrombotic thrombocytopenia (VITT) is characterized by the onset of venous or arterial thrombosis in temporal relationship to the administration of anti-Sars-Cov-2 viral vector vaccines (ChAdOx1 nCov-19 and Ad26.
View Article and Find Full Text PDFArticle Synopsis
- A study compared the effectiveness of four biologic drugs—adalimumab, infliximab biosimilar, golimumab, and vedolizumab—used to treat ulcerative colitis (UC) in Italy, focusing on achieving continuous clinical remission (CCR).
- Researchers analyzed data from 416 UC patients treated from 2014 to 2019, measuring success based on a strict CCR definition over one year.
- Results showed similar CCR rates among the four drugs, with vedolizumab proving more effective for patients who had previously failed anti-TNFα treatments, while safety profiles were comparable across all drugs.
Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn's disease (CD), but few real-life data have been reported in this population.
Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients.
Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017.
Video 1Endoscopic management of recurrent cholangitis after EUS-guided choledochoduodenostomy.
View Article and Find Full Text PDF